Literature DB >> 11460947

Penicilliosis-associated hemophagocytic syndrome in a human immunodeficiency virus-infected child: the first case report in children.

K Chokephaibulkit1, G Veerakul, N Vanprapar, A Chaiprasert, V Tanphaichitr, S Chearskul.   

Abstract

Infection-associated hemophagocytic syndrome (IAHS) has been found in many systemic infectious conditions with a high mortality rate. Disseminated Penicillium marneffei infection is a common opportunistic condition among HIV-infected patients in many regions in Southeast Asia. We report the first case of IAHS caused by penicilliosis in an HIV-infected child who presented with cytopenias and recovered promptly after antifungal and intravenous immunoglobulin therapy.

Entities:  

Mesh:

Year:  2001        PMID: 11460947

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  4 in total

Review 1.  Characteristics and Prognosis of Talaromyces marneffei Infection in HIV-positive Children in Southern China.

Authors:  Xiaochun Xue; Jun Zou; Wenjie Fang; Xiaogang Liu; Min Chen; Amir Arastehfar; Macit Ilkit; Yanqing Zheng; Jianglong Qin; Zhipeng Peng; Dongying Hu; Wanqing Liao; Weihua Pan
Journal:  Mycopathologia       Date:  2022-02-14       Impact factor: 2.574

2.  Hemophagocytic syndrome: an unusual manifestation of acute human immunodeficiency virus infection.

Authors:  Te-Li Chen; Wing-Wai Wong; Tzeon-Jye Chiou
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

Review 3.  Debate around infection-dependent hemophagocytic syndrome in paediatrics.

Authors:  Valentina Ansuini; Donato Rigante; Susanna Esposito
Journal:  BMC Infect Dis       Date:  2013-01-16       Impact factor: 3.090

4.  Talaromycosis-Associated Secondary Hemophagocytic Lymphohistiocytosis in Nine Human Immunodeficiency Virus-Negative Patients: A Multicenter Retrospective Study.

Authors:  Mianluan Pan; Ye Qiu; Wen Zeng; Shudan Tang; Xin Feng; Jingmin Deng; Xuan Wei; Zhiyi He; Jianquan Zhang
Journal:  Infect Drug Resist       Date:  2019-12-04       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.